|National Institutes of Health (NIH) | National Cancer Institute (NCI) | Technology Transfer Center||Supervisor, Invention Development and Marketing Unit||USA|
WHAT ARE THE RECENT INITIATIVES TO DE-RISK ASSETS OF ACADEMIC ORIGIN?
Dr. Michael Salgaller leads the Invention Development and Marketing Unit within the National Cancer Institute’s Technology Transfer Center, where he leverages over 20 years of business, scientific, and investment experience in various life science sectors to support technology development and commercialization. Previously, he provided technical and strategic expertise to The Conafay Group, a DC-based government affairs firm – leading efforts on non-dilutive funding and alliance development. Previously, he was a key member of the business development team for the healthcare practice at SAIC, a Fortune-500 government contractor. He helped lead and deepen relationships with the Department of Health and Human Services – especially NIH and FDA – as well as foundations and patient advocacy groups. Before SAIC, he was a long-time industry executive who has held various positions in early-stage biotechnology and boutique professional service firms. In addition, Dr. Salgaller was on the investment team of Toucan Capital, a $120M early-stage venture firm dedicated to the life sciences, where he guided company formation and helped raise follow-on financing. He began his career as a Senior Staff Scientist with Dr. Steve Rosenberg at the National Cancer Institute, where he oversaw a lab developing immunotherapies for patients with terminal cancer.
Dr. Salgaller serves on the Life Sciences Advisory Board of the Maryland-Israel Development Center, as well as NCI liaison to the Maryland Technology Council. He is an advisor to DC ArchAngels and the Cooperative Angel Alumni Group. He is the author of “Biotechnology Entrepreneurship,” which is used as a reference text for courses at NIH and Catholic University, among others. He is the author of over 100 articles, presentations, and book chapters, and is on the editorial boards of several journals. Dr. Salgaller received his PhD in Pathology from The Ohio State University.